Impact Analysis of Covid-19
The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
With the slowdown in world economic growth, the Antibody-drug Conjugates Industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Antibody-drug Conjugates market size to maintain the average annual growth rate of 15 from XXX million $ in 2014 to XXX million $ in 2018, Stratagem Market Insights analysts believe that in the next few years, Antibody-drug Conjugates market size will be further expanded, we expect that by 2023, The market size of the Antibody-drug Conjugates will reach XXX million $.
Antibody-drug conjugates are class of highly potent biological drugs that combine monoclonal antibodies specific to surface antigens which are present on particular tumor cells with highly potent anti-cancer agents associated with a chemical linker. These drugs are especially used to treat cancer by targeting and killing tumor cells while sparing healthy cells present around. These drugs offer very high specificity to the targeted cells while maximizing their efficacy and minimizing the side-effects associated. Blood cancer, lung cancer, breast cancer, and brain tumor are some of the major application areas of antibody-drug conjugates.
Rising prevalence of cancer around the globe due unhealthy lifestyle is expected to propel the market growth of antibody-drug conjugates over the forecast period. According to the World Health Organization, cancer is the second leading cause of death globally and is responsible for an estimated 9.6 million deaths in 2018. Moreover, the rising number of partnerships among major players for developing and commercializing the advanced antibody-drug conjugates is further expected to foster market growth. For instance, in March 2019, AstraZeneca has entered into a development and commercialization collaboration agreement with Daiichi Sankyo Company, Limited (Daiichi Sankyo) for trastuzumab deruxtecan (DS-8201), an antibody-drug conjugate (ADC) and potential new targeted medicine for cancer treatment.
From the geographical perspective, North America is expected to gain significant growth over the forecast period and this can be attributed to the presence of a well-established healthcare industry and rising expenditure on healthcare by the government in the region. According to The Centers for Medicare & Medicaid Services, the U.S. health care spending grew 4.6 percent in 2018, reaching $3.6 trillion or $11,172 per person. As a share of the nation's Gross Domestic Product, health spending accounted for 17.7 percent.
Key Developments:
- In December 2019, Astellas Pharma Inc. and Seattle Genetics, Inc. announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval to PADCEV™ for the treatment of adult patients with locally advanced or metastatic urothelial cancer. It is a first-in-class antibody-drug conjugate (ADC) that is directed against Nectin-4, a protein located on the surface of cells and highly expressed in bladder cancer
- In December 2015, Ajinomoto Althea, Inc. a provider of biopharmaceutical contract development and manufacturing services, announced that it is expanding its existing biological drug product manufacturing operations to include highly active materials such as Antibody Drug Conjugates (ADCs).
- In September 2017, Glythera has teamed up with antibody developer IONTAS to develop a new generation of antibody-drug conjugate (ADC) drugs. As part of the agreement, IONTAS will develop new antibodies against multiple undisclosed targets.
This Report covers the manufacturers' data, including shipment, price, revenue, gross profit, interview record, business distribution, etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including market size, volume, and value, as well as price data.
Besides, the report also covers segment data, including type segment, industry segment, channel segment, etc. cover different segment market sizes, both volume, and value. Also cover different industries client's information, which is very important for the manufacturers. If you need more information,
Section 1: Definition
Section (2 3): Manufacturer Detail
╼ ImmunoGen
╼ Seattle Genetics
╼ Roche
╼ Takeda
Section 4: Region Segmentation
╼ North America Country (United States, Canada)
╼ South America
╼ Asia Country (China, Japan, India, Korea)
╼ Europe Country (Germany, UK, France, Italy)
╼ Other Country (Middle East, Africa, GCC)
Section (5 6 7): Type Segmentation
Product Type Segmentation ⤍
╼ Adcetris
╼ Kadcyla
Industry Segmentation ⤍
╼ Breast Cancer
╼ Lymphoma
Channel (Direct Sales, Distributor) Segmentation
Section 8: Trend (2019-2026)
Section 9: Product Type Detail
Section 10: Downstream Consumer
Section 11: Cost Structure
Section 12: Conclusion
